349 related articles for article (PubMed ID: 17597196)
21. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
22. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
23. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
Sutton G; Blessing JA; Ball H
Gynecol Oncol; 1999 Sep; 74(3):346-9. PubMed ID: 10479491
[TBL] [Abstract][Full Text] [Related]
25. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
Smith HO; Blessing JA; Vaccarello L
Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
Yi-Shin Kuo D; Timmins P; Blank SV; Fields AL; Goldberg GL; Murgo A; Christos P; Wadler S; Runowicz CD
Gynecol Oncol; 2006 Jan; 100(1):160-5. PubMed ID: 16198398
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
30. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
Jewell EL; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063
[TBL] [Abstract][Full Text] [Related]
31. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Levine AM; Tulpule A; Quinn DI; Gorospe G; Smith DL; Hornor L; Boswell WD; Espina BM; Groshen SG; Masood R; Gill PS
J Clin Oncol; 2006 Apr; 24(11):1712-9. PubMed ID: 16520466
[TBL] [Abstract][Full Text] [Related]
34. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
Pujol JL; Breton JL; Gervais R; Tanguy ML; Quoix E; David P; Janicot H; Westeel V; Gameroff S; Genève J; Maraninchi D
J Clin Oncol; 2007 Sep; 25(25):3945-51. PubMed ID: 17761978
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
37. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
